查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008084

叢狀神經纖維瘤治療市場：依藥物類別、患者群、通路和地區分類

Plexiform Neurofibromas Treatment Market, By Drug Class, By Patient Population, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2026年，神經叢神經纖維瘤治療市場規模估計為18.88億美元，預計2033年將達到32.65億美元。預計從2026年到2033年，該市場將以8.4%的複合年成長率成長。

分析範圍 分析詳情
基準年 2025 市場規模（2026 年） 18.88億美元
效能數據 2020-2024 預測期 2026-2033
預測期（2026-2033 年）複合年成長率 8.40% 預計金額（2033 年） 32.65億美元

叢狀神經纖維瘤是第一型神經纖維瘤的一種罕見亞型，表現為隆起、畸形的腫塊，起源於多條神經，並延伸至結締組織和皮膚褶皺處。神經纖維瘤是一種遺傳性神經系統疾病，可涉及皮膚、神經、腦部和脊髓。神經纖維瘤（或稱為腫瘤）可沿著體內神經生長，也可生長於皮膚表面或皮下。神經纖維瘤分為三種類型，每種類型都有其特定的症狀和體徵：1型神經纖維瘤（NF1）、2型神經纖維瘤（NF2）和雪旺氏細胞瘤病。叢狀神經纖維瘤是第1型神經纖維瘤（NF1）的一種病理特異性觀察，也是神經纖維瘤的常見併發症。叢狀神經纖維瘤主要為遺傳性腫瘤，可發生於身體任何部位，包括頭頸部、四肢、脊椎周圍以及體內深處，並可能涉及器官。叢狀神經纖維瘤通常在嬰兒期確診，約30%的NF1患者會出現這種腫瘤。叢狀神經纖維瘤範圍廣泛，涉及長神經纖維及其分支，並且常常突破神經膜，並侵入周圍組織。

市場動態

預計在預測期內，採用有機成長策略，例如獲得美國食品藥物管理局(FDA) 等監管機構的產品核可，將推動全球神經叢神經纖維瘤治療市場的成長。例如，2020 年 4 月，生物製藥公司Astra Zeneca宣布，其藥物Selumetinib （商品名為「Koselugo」）已獲得美國食品藥物管理局(FDA) 的核准，用於治療 2 歲及以上兒童的1 型神經纖維瘤病。 Selumetinib 是一種激酶抑制劑，也是第一個核准用於治療方法兒童神經纖維瘤的藥物。

本報告的主要特點

  • 本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
  • 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
  • 本節根據以下參數介紹全球神經叢神經纖維瘤治療市場中主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
  • 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
  • 《全球叢狀神經纖維瘤治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員可以透過分析全球神經叢神經纖維瘤治療市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 影響分析
  • 市場趨勢
  • PEST分析
  • 波特五力分析
  • 主要進展
  • 品牌分析
  • 企業合併和商業聯盟的趨勢
  • 流行病學
  • 產品核准和發布
  • 治療流程
  • 治療方案分析
  • 作用部位（作用機轉）
  • 主要企業的新投資
  • 製造商銷售
  • 疾病意識計劃
  • 各國醫療費用支出

第4章：全球叢狀神經纖維瘤治療市場：依藥物類別分類（2020-2033 年）

  • 概述
  • Selumetinib
  • 非類固醇消炎劑（NSAIDs）
  • 抗驚厥藥物
  • 其他（例如，三環抗憂鬱藥物）

第5章：全球神經纖維瘤治療市場：依病患群體分類（2020-2033 年）

  • 概述
  • 兒童
  • 成人

第6章：全球叢狀神經纖維瘤治療市場：依通路分類（2020-2033 年）

  • 概述
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球叢狀神經纖維瘤治療市場：按地區分類（2020-2033 年）

  • 北美洲
    • 美國
  • 加拿大
  • 拉丁美洲
    • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 歐洲
    • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
    • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東
    • GCC
  • 以色列
  • 其他中東國家
  • 非洲
    • 北非
  • 中非
  • 南非

第8章 競爭情勢

  • AstraZeneca
  • Pfizer Inc.
  • Sun Pharmaceuticals Industries Limited
  • Mallinckrodt Pharmaceuticals
  • SpringWorks Therapeutics
  • Alcaliber SA
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Apotex Inc.
  • Mylan NV
  • GSK plc.
  • Solara Active Pharma Sciences Ltd.
  • Abbott
  • Shanghai Kechow Pharma, Inc.
  • Endo Pharmaceuticals Inc.
  • Purdue Pharma LP
  • Merck &Co., Inc.
  • NFlection Therapeutics
  • Healx
  • Array Biopharma

第9章

  • 分析方法
  • 關於 Coherent Market Insights
簡介目錄
Product Code: CMI5430

Plexiform Neurofibromas Treatment Market is estimated to be valued at USD 1,888.0 Mn in 2026 and is expected to reach USD 3,265.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1,888.0 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 8.40% 2033 Value Projection: USD 3,265.0 Mn

Plexiform neurofibromas is an uncommon variant of neurofibromatosis type 1 that arises from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. Neurofibromatosis is a genetic neurological disorder which can affect the skin, nerves, brain, and spinal cord. Neurofibromas or tumors, grow along the body's nerves or on or underneath the skin. There are three types of neurofibromatosis that are associated with unique symptoms and signs, Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and Schwannomatosis. Plexiform neurofibromas are essentially pathognomonic of neurofibromatosis type 1 (NF1) which is a common complication of neurofibromatosis. Plexiform neurofibromas are predominantly inherited tumors that can occur anywhere in the body. This includes the head and neck, extremities, areas around the spine and deep in the body where they may affect organs. Plexiform neurofibromas are usually diagnosed in early childhood. They are found in approximately 30% of patients with NF1. Plexiform neurofibromas diffusely involve long nerve segments and its branches, often extending beyond the epineurium into the surrounding tissue.

Market Dynamics

Adoption of inorganic strategies, such as product approval, by regulatory authority such as the U.S. Food and Drug Administration is expected to drive the global plexiform neurofibromas treatment market growth over the forecast period. For instance, in April 2020, AstraZeneca, a biopharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Selumetinib under the brand name Koselugo, for pediatric patients, 2 years of age and older, with neurofibromatosis type 1. Selumetinib is a kinase inhibitor and the first therapy approved for pediatric patients with neurofibromatosis.

Key features of the study

  • This report provides an in-depth analysis of the global plexiform neurofibromas treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plexiform neurofibromas treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, SpringWorks Therapeutics, Alcaliber S.A, Teva Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Apotex Inc., Mylan N.V., GSK plc., Solara Active Pharma Sciences Ltd., Abbott, Shanghai Kechow Pharma, Inc., Endo Pharmaceuticals Inc., Purdue Pharma L.P, Merck & Co., Inc., NFlection Therapeutics, Healx, and Array Biopharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global plexiform neurofibromas treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plexiform neurofibromas treatment market

Market Segmentation

  • By Drug Class (Revenue, USD Mn, 2020 - 2033)
    • Selumetinib
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Anticonvulsants
    • Others (Tricyclic Antidepressants, etc.)
  • By Application Insights (Revenue, USD Mn, 2020 - 2033)
    • Pediatric
    • Adult
  • By End User Insights (Revenue, USD Mn, 2020 - 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region Insights (Revenue, USD Mn, 2020 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
  • Key Players
    • AstraZeneca
    • Pfizer Inc.
    • Sun Pharmaceuticals Industries Limited
    • Mallinckrodt Pharmaceuticals
    • SpringWorks Therapeutics
    • Alcaliber S.A
    • Teva Pharmaceutical Industries Ltd.
    • Glenmark, Amneal Pharmaceuticals LLC
    • Aurobindo Pharma
    • Apotex Inc.
    • Mylan N.V.
    • GSK plc.
    • Solara Active Pharma Sciences Ltd.
    • Abbott
    • Shanghai Kechow Pharma, Inc.
    • Endo Pharmaceuticals Inc.
    • Purdue Pharma L.P.
    • Merck & Co., Inc.
    • NFlection Therapeutics
    • Healx
    • Array Biopharma

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Patient Population
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • PEST Analysis
  • PORTER's Analysis
  • Key Developments
  • Brand Analysis
  • Merger and Collaboration Scenario
  • Epidemiology
  • Product Approvals/Launches
  • Treatment Algorithm
  • Treatment Option Analysis
  • Site of Activity (Mode of Action)
  • New Investments by Major Market Players
  • Manufacturer Revenue
  • Disease Awareness Programs
  • Healthcare Spending by Country

4. Global Plexiform Neurofibromas Treatment Market, By Drug Class, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Selumetinib
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Anticonvulsants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Others (Tricyclic Antidepressants, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Plexiform Neurofibromas Treatment Market, By Patient Population, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Pediatric
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Plexiform Neurofibromas Treatment Market, By Distribution Channel, 2020-2033, (USD Mn)

  • Overview
    • Market Share Analysis, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, 2020-2033
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Plexiform Neurofibromas Treatment Market, By Region, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2020-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • U.S.
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Canada
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • Brazil
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Mexico
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Argentina
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Latin America
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • U.K.
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Germany
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Italy
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • France
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Spain
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Russia
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Europe
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • China
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • India
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Japan
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • ASEAN
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Australia
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • South Korea
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Asia Pacific
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
      • GCC
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Israel
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Rest of Middle East
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
      • North Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • Central Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
  • South Africa
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Population, 2020 - 2033, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)

8. Competitive Landscape

  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sun Pharmaceuticals Industries Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mallinckrodt Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SpringWorks Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Alcaliber S.A
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amneal Pharmaceuticals LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aurobindo Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Apotex Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Solara Active Pharma Sciences Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shanghai Kechow Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Endo Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Purdue Pharma L.P
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NFlection Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Healx
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Array Biopharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us